Geron Corp GERN:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD

After Hours: Last | 05/06/24 EDT

3.74

+0.01 (+0.27%)

Volume

34,118

3.73UNCH (UNCH)

Volume

6,637,329

52 week range

1.64 - 4.30

Open3.95
Day High3.95
Day Low3.68
Prev Close3.73
52 Week High4.30
52 Week High Date04/29/24
52 Week Low1.64
52 Week Low Date03/13/24

Key Stats

Market Cap2.212B
Shares Out593.13M
10 Day Average Volume11.79M
Dividend-
Dividend Yield-
Beta0.46
YTD % Change76.78

KEY STATS

Open3.95
Day High3.95
Day Low3.68
Prev Close3.73
52 Week High4.30
52 Week High Date04/29/24
52 Week Low1.64
52 Week Low Date03/13/24
Market Cap2.212B
Shares Out593.13M
10 Day Average Volume11.79M
Dividend-
Dividend Yield-
Beta0.46
YTD % Change76.78

RATIOS/PROFITABILITY

EPS (TTM)-0.35
P/E (TTM)-10.77
Fwd P/E (NTM)-10.45
EBITDA (TTM)-193.502M
ROE (TTM)-112.29%
Revenue (TTM)237,000.003
Gross Margin (TTM)-
Net Margin (TTM)-77,690.72%
Debt To Equity (MRQ)33.05%

EVENTS

Earnings Date08/01/2024(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest On Geron Corp

Cramer's Lightening Round: BTU, TTD, GERNApril 10, 2024CNBC.com
Cramer's Lightning Round: Trade Desk is 'great'April 10, 2024CNBC.com

Content From Our Affiliates

Buy Rating Affirmed: Anticipating Imetelstat’s Approval and Market PotentialMay 2, 2024TipRanks
Biotech Alert: Searches spiking for these stocks todayMay 2, 2024TipRanks
Geron reports Q1 EPS (9c), consensus (10c)May 2, 2024TipRanks
Analysts Conflicted on These Healthcare Names: Dyne Therapeutics (DYN) and Geron (GERN)April 30, 2024TipRanks
Geron downgraded to Neutral from Outperform at BairdApril 30, 2024TipRanks

Profile

Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical...

John Scarlett M.D.

Chairman of the Board, President, Chief Executive Officer

Andrew Grethlein Ph.D.

Executive Vice President, Chief Operating Officer

Michelle Robertson

Chief Financial Officer, Executive Vice President - Finance, Treasurer

Scott Samuels Esq.

Executive Vice President, Chief Legal Officer, Secretary

Melissa Behrs

Executive Vice President - Business Operations, Chief Alliance Officer

Address

919 East Hillsdale Boulevard, Suite 250

Foster City, CA

94404

United States

https://www.geron.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
KURA Kura Oncology Inc	21.01	UNCH	UNCH
DYN Dyne Therapeutics Inc	26.25	UNCH	UNCH
KROS Keros Therapeutics Inc	60.26	UNCH	UNCH
RNA Avidity Biosciences Inc	26.33	UNCH	UNCH
CLDX Celldex Therapeutics Inc	41.65	UNCH	UNCH